The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
As the country broadens COVID-19 vaccine distribution efforts, the latest research from the KFF COVID-19 Vaccine Monitor finds that side effects, including allergic reactions and long-term consequences, are the public’s top concern about getting vaccinated when asked to describe what worries them in their own words.
This issue brief examines key issues related to multi-dose vaccination series generally as well as issues specific to COVID-19.
Updated analysis of state-reported data as of February 1, 2021 on COVID-19 vaccinations, cases, and deaths by race/ethnicity is now available.
Additional Data Available Through Online Vaccine Monitor Dashboard As vaccination efforts ramp up across the country, the KFF COVID-19 Vaccine Monitor examines where the public is getting its relevant information.
During the 53rd week since the first coronavirus case appeared in the United States, the world surpassed 100 million COVID-19 cases, with the United States accounting for a quarter of them. The U.S. also accounts for one-fifth (433,200) of the world’s nearly 2.2 million reported deaths.
Most Convincing Messages to Promote Vaccination Highlight Effectiveness at Preventing Illness and a Return to Normal Life; Hearing about Rare Allergic Reactions and Side Effects May Discourage Some New KFF Dashboard Features Key Data and Insights from the Vaccine Monitor With millions of Americans getting their first COVID-19 vaccinations, the public’s eagerness to get a…
This brief reviews why racial diversity within COVID-19 vaccine clinical trials is important, discusses the barriers to participation in clinical trials among people of color, and examines the racial/ethnic composition of clinical trial participants for the Pfizer-BioNTech and Moderna vaccines.
Debate about how many vaccinations are needed by when has been in the news. Drew Altman lays it out in his latest column.
During the 52nd week since the first coronavirus case appeared in the United States, the U.S. surpassed 24.6 million total cases and 410,100 deaths due to the pandemic. Here’s our recap of the past week in the coronavirus pandemic from our tracking, policy analysis, polling, and journalism.
A new Policy Watch, Early State Vaccination Data Raise Warning Flags for Racial Equity, explores the latest state-reported data on vaccination by race/ethnicity available on KFF’s COVID-19 state data and policy tracker.
© 2025 KFF